Novartis (NOVN.SW,NVS) announced top-line results from its Phase III clinical trials—NEPTUNUS-1 and NEPTUNUS-2—evaluating ianalumab (VAY736) in adults with active Sjögren's disease, a chronic and debilitating autoimmune condition.
Both studies met their primary endpoints, showing statistically significant improvements in disease activity. These findings reinforce the potential of ianalumab to become the first targeted therapy for Sjögren's disease.
Ianalumab features a dual mechanism of action—combining B-cell depletion with BAFF-R inhibition—designed to address the underlying immune dysfunction in patients. The results mark a major step forward in the development of precision treatments for autoimmune disorders, Novartis said in a statement.
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.